Extrawell Pharmaceutical Holdings Limited (HKG:0858)
Hong Kong · Delayed Price · Currency is HKD 0.0820
+0.0120 (17.14%)
Jul 13, 2026, 2:44 PM HKT
HKG:0858 Revenue
In the fiscal year ending March 31, 2026, Extrawell Pharmaceutical Holdings had annual revenue of 51.48M HKD, down -7.12%. Extrawell Pharmaceutical Holdings had revenue of 23.47M in the half year ending March 31, 2026.
Revenue
51.48M
Revenue Growth
-7.12%
P/S Ratio
3.94
Revenue / Employee
325.83K
Employees
158
Market Cap
203.00M
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 51.48M | -3.95M | -7.12% |
| Mar 31, 2025 | 55.43M | -3.67M | -6.21% |
| Mar 31, 2024 | 59.10M | -13.48M | -18.57% |
| Mar 31, 2023 | 72.58M | -1.35M | -1.82% |
| Mar 31, 2022 | 73.93M | -4.88M | -6.19% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Zhongzhi Pharmaceutical Holdings | 1.93B |
| Lee's Pharmaceutical Holdings | 1.44B |
| Shenzhen Neptunus Interlong Bio-technique Company | 1.08B |
| Kontafarma China Holdings | 914.71M |
| Wai Yuen Tong Medicine Holdings | 721.27M |
| Qianhai Health Holdings | 677.12M |
| PuraPharm Corporation | 336.11M |
| Tianda Pharmaceuticals | 322.95M |
Extrawell Pharmaceutical Holdings News
- 6 months ago - Extrawell Pharmaceutical CEO Xie Yi To Resign, Guo Yi To Be New CEO - Nasdaq